Bayer feels cost of restructuring
March 25, 2004German pharmaceutical company Bayer has posted the biggest losses in its history after paying a hefty price for restructuring the …
Solvay and Altana to swap detailing time
March 25, 2004Altana Pharma and Solvay Healthcare are to launch a novel 'time-swap' co-promotional agreement to make the most of their salesforces' …
France pours cold water on Novartis talks
March 25, 2004Merger talks between Swiss pharma company Novartis and Franco-German Aventis could be in jeopardy after the French government indicated its …
New code for journals in wake of MMR conflict of interest
March 19, 2004MMR, journals
A new code of conduct has been drawn up for medical journals to help uncover conflicts of interest which could …
UK and US face up to public health crises
March 19, 2004The UK government has launched a consultation that it hopes will stimulate debate on how best to tackle the growing …
Serious concerns could delay Zocor switch
March 17, 2004Serious concerns have been expressed about plans to sell statins over the counter, and could hold up the POM to …
Novartis ponders tie-up with Aventis
March 8, 2004Aventis may have found its 'white knight' to save it from a hostile takeover from Sanofi-Synthelabo, in the shape of …
MMR researchers withdraw claim
March 4, 2004MMR
Ten doctors who co-authored the controversial UK study which linked the MMR jab to autism have withdrawn their support for …
Making the most of CRM
March 4, 2004In recent years, pharma companies have spent considerable sums on introducing customer relationship management (CRM). However, our research into the …
Elan fall-out provides launch pad for new company
March 4, 2004The withdrawal of Elan from Europe has provided a new platform for the launch of a new niche player in …
McClellan’s new job stirs political controversy
March 2, 2004The head of the FDA Mark McClellan is to quit his post in order to lead the reform of the …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
